New book by Larry Connors Click here Improve your trading - See how
The Natick, Mass.-based company manufactures pacemakers and implantable heart defibrillators at a facility in Arden Hills, which it acquired in 2006 as part of a high-stakes bidding war for Guidant.
The misdemeanor charges are related to failure to include information in reports to the Food and Drug Administration, the company said.
In May 2005, the Twin Cities-dominated industry for heart rhythm devices was rocked by revelations that Joshua Oukrop, 21, of Grand Rapids, Minn. had died suddenly while mountain biking in Utah.
Oukrop's doctors had implanted in his chest a Guidant Ventak Prizm 2 defibrillator, a device that's meant to provide a life-saving jolt for patients with dangerous heart rhythms. But doctors in Minneapolis told the New York Times that the device failed to rescue Oukrop because of a product defect that the company failed to disclose to doctors and patients.
At the time, Oukrup's death was the only one linked to the problem. But the disclosure brought with it a series of high-profile product recalls, and word of more patients and families who claimed harm.
Boston Scientific said this morning it had previously disclosed an investigation into the matter by the U.S. Attorney's Office in Minneapolis. The products involved in the investigation, the company said, were the Ventak Prizm 2, the Contak Renewal and the Contak Renewal 2 devices, which were subject to a product recall in 2005.
"We are pleased this investigation has been resolved," said Ray Elliott, president and chief executive officer of Boston Scientific, in a statement.
"Guidant and its employees acted in good faith and believed they complied with applicable laws and regulations," he said. "We elected to resolve this matter so we could put it behind us and devote our full energies and resources to developing our innovative technologies."
Accounting rules require the company to record the agreement in the third quarter; accordingly, Boston Scientific has updated financial results for the quarter to include a $294 million charge -- reflecting the $296 million charge and a $2 million reversal of a related accrual.
Boston Scientific shares were trading up 6 cents this morning at $8.11.
To see more of the Pioneer Press, or to subscribe to the newspaper, go to http://www.twincities.com. Copyright (c) 2009, Pioneer Press, St. Paul, Minn. Distributed by McClatchy-Tribune Information Services. For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
